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Epidemiological data for 
hepatitis D in Africa
The systematic review on the 
seroprevalence of hepatitis D virus 
in sub-Saharan Africa by Alexander 
Stockdale and colleagues1 is a key 
contribution to the epidemiology 
of hepatitis D virus infection, and 
highlights the scarcity of reliable 
data from the African continent. 
Most of the studies included in 
this meta-analysis were based on 
convenience sampling, and less 
than half of these studies include 
a confirmation of hepatitis D virus 
infection by a molecular test. The 
Article concludes that there is a need 
for reliable epidemiological data that 
are representative of the general 
population, that there are localised 
clusters of hepatitis D virus endemicity, 
and that there is a need for reliable 
hepatitis D virus testing methods.
The first international assessment 
of external quality control for 
hepatitis D virus RNA quantification 
demonstrated the insufficient 
performances of several assays to 
detect viruses circulating in Africa 
(ie, genotypes 1 and 5–8).2 Although 
new, improved assays have been 
developed,3 implementation of PCR 
to detect hepatitis D virus remains 
challenging in Africa. Collection of 
dried blood spot (DBS) samples is 
a promising way to facilitate access 
to nucleic acid testing. WHO has 
recently recommended serological 
and molecular testing on DBS 
specimens as an alternative to blood 
samples for the diagnosis of hepatitis 
B and hepatitis C and for large 
epidemiological surveillance studies in 
under-resourced regions and remote 
areas.4 From our experience, DBS 
samples can also be used to detect 
hepatitis D virus antibodies and RNA 
in samples over 10 000 IU/mL.
In a study supported by the 
French National Agency for AIDS 
Research (ANRS 12270), DBS 
samples collected from more than 
15 000 adult volunteers during 
the 2010 Demographic and Health 
Survey in Burkina Faso in west Africa 
were tested for hepatitis D virus 
infection. Among HBsAg carriers, 
the seroprevalence estimates of 
hepatitis D virus were 1·1% (95% CI 
0·6–1·6) countrywide, 1·4% (0·7–2·0) 
in men, and 0·7% (0·1–1·4) in women. 
Heterogeneous geographical distri-
bution of seroprevalence was observed, 
with estimates of 5·4% (2·2–8·6) 
in Cascades and 8·7% (2·5–15·0) in 
Sud-Ouest regions, suggesting local 
clusters of endemicity (figure).
These results highlight that 
DBS specimens collected during 
Demographic and Health Surveys 
and having large samples could be 
useful for estimating the prevalence 
of diseases, allowing reliable country-
wide and regional distribution of 
prevalence estimates. We suggest 
that such surveys might provide 
opportunities to fill the gaps in the 
knowledge of epidemic hepatitis 
infections and to guide national 
and regional infection control 
programmes.
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Figure: Countrywide prevalence of anti-hepatitis D virus antibodies in Burkina Faso among HBsAg 
carriers
